Gitnux/Report 2026

AI Pharmaceutical Industry Statistics

AI is shaving months off every stage from target finding to trials, with recruitment time cut 75% by ML matching and Phase 1 failure dropping from 30% to 15% across 20 pharma collaborations. At the same time, the pipeline is accelerating at an industrial pace, with AI drug discovery projected to reach USD 11.9 billion by 2033 and pharma startups raising over USD 4.5 billion in 2023 while regulators tighten validation expectations.
261Statistics
93Sources
12Sections
1Visuals
47mRead
November 10, 2026Updated
AI Pharmaceutical Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Edited by Karl Becker·Fact-checked by Rajesh Patel
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The ai pharmaceutical industry at a glance

AI in pharmaceuticals is moving from pilot projects into core drug-development workflows: the global market was estimated at $3.8 billion in 2025 and is forecast to reach $15.2 billion by 2030.

$3.8B[70]
Global market size, 2025
31.7%[70]
Forecast CAGR, 2025–2030
59.5%[70]
North America share, 2024
38.06%[69]
Drug-discovery VC deals, 2010–2024
Market size
BCC Research estimated the global artificial-intelligence-in-pharmaceuticals market at $3.8 billion in 2025. A separate 2025 estimate from Fortune Business Insights placed the broader AI-in-pharma-and-biotech market at $6.63 billion, reflecting differences in scope and market definitions.[70][71]
Forecast & CAGR
BCC Research forecasts growth from $3.8 billion in 2025 to $15.2 billion in 2030, equivalent to a 31.7% CAGR. The Business Research Company forecasts a narrower 23.4% CAGR from $3.78 billion in 2025 to $11.12 billion in 2030.[70][72]
Market share & regions
North America accounted for 59.5% of the global AI-in-pharmaceuticals market in 2024 in BCC Research’s regional estimate, compared with 17.2% for Europe and 12.5% for Asia-Pacific. Clarivant Health estimated North America’s share at 48.6% in 2025, illustrating the effect of different market boundaries and methodologies.[70][73]
Segmentation
Clarivant Health estimated drug discovery and preclinical research as the largest application segment, with a 31.0% share of the global AI-in-pharmaceutical market in 2025. The market is also divided across clinical development, manufacturing and quality, pharmacovigilance and regulatory work, and commercial and medical affairs.[73]
Key players & concentration
The sector includes platform companies, AI-native drug-discovery firms, pharmaceutical companies and technology providers; examples include Insilico Medicine, Genesis Molecular AI, Owkin, Cradle and XtalPi. A 2010–2024 analysis of 1,679 AI-related biopharmaceutical venture-capital deals found drug discovery was the largest focus, representing 639 deals, or 38.06%, but it did not establish a company-level market-concentration ratio.[69][74][75]
Pricing
No reliable, comparable industry-wide pricing dataset was identified for AI pharmaceutical software, platform subscriptions or AI-enabled discovery services. Public partnership announcements generally disclose milestone-based or contingent deal values rather than standardized prices.[76][53]
Trends, drivers & challenges
Growth is being driven by generative models, multimodal biological data, automated design–make–test cycles and demand to reduce discovery time and development costs. Key challenges remain model validation, data governance, cybersecurity, explainability, reproducibility and the limited clinical evidence needed to show that AI-generated candidates improve outcomes.[77][69]
Consumer behavior & competition
The principal buyers are pharmaceutical and biotechnology companies, CROs and CDMOs rather than end consumers. Competition is increasingly organized around partnerships and licensing: for example, Boehringer Ingelheim licensed Owkin’s K Pro AI Scientist and multimodal data in September 2026, while Incyte expanded its collaboration with Genesis Molecular AI in May 2026.[73][78][75]
M&A
AI-related pharmaceutical M&A remained more limited than partnerships, but Roche announced a definitive agreement in May 2026 to acquire PathAI, combining Roche’s companion-diagnostics position with PathAI’s AI pathology platform. The transaction followed a partnership between the companies that began in 2021 and expanded in 2024.[79]
Regulation
In January 2026, FDA and EMA published 10 guiding principles for good AI practice in drug development, covering human-centric design, risk-based oversight, data governance, model performance assessment and lifecycle management. FDA also issued draft guidance in January 2025 for assessing the credibility of AI models used in drug and biological product submissions, drawing on experience with more than 500 submissions containing AI components since 2016.[77]
Latest news
Recent activity has centered on large strategic collaborations rather than standalone software sales. In September 2026, Orbis Medicines announced a Novo Nordisk collaboration worth up to $1.4 billion for AI-enabled macrocycle discovery, while Owkin announced a license agreement with Boehringer Ingelheim for its AI Scientist and multimodal oncology and immunology data.[76][78]

02 Ranking

Top 10 Companies in the Ai Pharmaceutical Industry

The leading companies in the ai pharmaceutical industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 9, 2026 · Next review December 9, 2026

Verdict

Insilico Medicine leads Gitnux's 2026 ai pharmaceutical ranking with an Overall score of 9.3, with its Pharma.AI platform generating seven clinical-stage programs and 31 internal programs. Generate:Biomedicines is the runner-up at 9.2, driven by machine learning and experimentation designing protein medicines with programs in Phase 3.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in AI drug discovery platforms

    Insilico Medicine

    US

    Ranked #1 · 9.3 · AI drug discovery platforms

    Why we picked it: It runs generative AI for drug discovery and development, with multiple programs produced via Pharma.AI.

    See in ranking ↓Visit insilico.com ↗

  2. Leader in computational chemistry software

    Schrödinger

    US

    Ranked #4 · 9.0 · Computational chemistry software

    Why we picked it: Its computational chemistry and AI stack spans software and drug-discovery workflows.

    See in ranking ↓Visit schrodinger.com ↗

  3. Leader in multimodal biology analytics

    insitro

    US

    Ranked #5 · 9.0 · Multimodal biology analytics

    Why we picked it: It targets multiple modality classes using machine learning and causal biology.

    See in ranking ↓Visit insitro.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the ai pharmaceutical industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Insilico Medicine

AI drug discovery platforms · US

9.3
2

Generate:Biomedicines

AI drug discovery platforms · US

9.2
3

Isomorphic Labs

AI drug discovery platforms · GB

9.1
4

Schrödinger

Computational chemistry software · US

9.0
5

insitro

Multimodal biology analytics · US

9.0
6

Recursion

AI-native drug discovery and clinical development · US

8.8
7

Owkin

Multimodal AI for drug discovery and development · FR

8.6
8

Iambic Therapeutics

AI-driven small-molecule therapeutics · US

8.5
9

Relay Therapeutics

AI-enabled precision small-molecule medicines · US

8.4
10

Xaira Therapeutics

Full-stack AI therapeutics discovery · US

8.3

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 9, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, February 13). Top 10 companies in the ai pharmaceutical industry. In AI Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/ai-pharmaceutical-industry-statistics/#top-companies

report visual · Comparison

AI in pharmaceuticals market share by region

North America holds the largest share at 59.5%.

North America59.5%
Europe17.2%
Asia-Pacific12.5%
Rest of the World10.8%
source-verifiedbccresearch.com

04 Statistics

Technology & Innovation

Technology & Innovation shows adoption moving into R&D and process development, with automation and generative workflows reported in 2024 and 2026.

AI in the ai pharmaceutical industry

  • 32% of AI/ML contributions in biopharmaceutical R&D supported drug design, while 31% supported target identification.[1]
  • 56% of biotech organizations using AI expected cost reductions within two years as automation and agentic workflows scaled in 2026.[2]
  • 55% of AI-adopting biopharma organizations applied AI in process development in 2024, including cell-line development, bioprocessing, formulation design and digital twins.[2]
  • AI/ML companies sponsored or collaborated in more than 35 biopharmaceutical trial starts annually in 2022, 2023 and 2024.[1]
  • Investor funding in AI-enabled drug discovery reached $8.40 billion in 2025, up from $4.10 billion in 2023.[3]
  • 50% of biotech organizations using AI reported faster time to target in 2026.[2]

Automation in the ai pharmaceutical industry

  • More than 55% of pharmaceutical organizations reported using process automation in IT operations, customer service or finance in 2025.[4]
  • 50% of pharmaceutical supply-chain respondents were investing in or evaluating automated packaging solutions over the following 12 to 18 months.[5]
  • 37% of small biopharma companies reported that more than 60% of laboratory instruments had automated data capture in 2024.[2]
  • Over 40% of pharmaceutical organizations reported that automation positively affected internal mobility and career progression in 2025.[4]
  • 48% of pharmaceutical supply-chain respondents cited a shortage of skilled talent or AI literacy as an obstacle to scaling AI and automation.[5]
  • 59% of pharmaceutical supply-chain respondents identified compliance automation as an investment priority.[5]

Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)

  • 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[6]
  • 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[7]
  • 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[8]
  • 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[8]
  • 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[6]

Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)

  • 55% of biopharma AI adopters reported using AI in process development in 2024.[9]
  • 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[10]
  • 70% of global biopharma respondents had adopted an R&D data platform in 2023.[10]
  • 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[2]
  • 63% of global biopharma respondents had adopted robotics and automation in 2023.[10]

Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)

  • 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[11]
  • 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[9]
  • 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[12]
  • 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[10]
  • 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[9]

Big Data in the pharmaceuticals and biotech sector (sector benchmark)

  • 43% of small and midsize pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[7]
  • 48% of pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[7]
  • 68% of pharmaceutical companies surveyed planned to use advanced analytics in 2024.[5]

05 Statistics

Data & Analytics

Data & Analytics highlights data structure and governance constraints, with 96% reporting data not well-structured or AI-ready for scaling in 2025.

Business intelligence in the ai pharmaceutical industry

  • 66% of surveyed life-sciences companies were experimenting with generative AI to test ideas and build use cases.[11]
  • 41% of US life-sciences organizations surveyed by EY used a decentralized AI-governance model in 2024.[13]
  • 21% was the improvement in patient-experience model prediction accuracy after Janssen implemented automated machine learning operations.[13]
  • 80% of surveyed biopharmaceutical executives expected generative AI to significantly affect real-world-evidence generation within the following year.[11]
  • 25% of surveyed biopharmaceutical executives said their companies had established generative-AI governance and oversight structures.[11]
  • 96% of surveyed biopharmaceutical companies considered real-world data and evidence essential to organizational strategy.[11]

Data analytics in the ai pharmaceutical industry

  • 18% of AI or machine-learning contributions by identified AI companies supported precision medicine in 2024.[1]
  • 48% of surveyed sponsor companies and CROs used AI or machine learning for patient-narrative analysis in clinical-trial activities.[14]
  • 50% of surveyed sponsor companies and CROs used AI or machine learning for genetic-data analysis in clinical-trial activities.[14]
  • 11% of nearly 80 surveyed companies had fully implemented AI or machine learning to support clinical-trial activities by late 2024.[14]
  • 13% of AI or machine-learning contributions by identified AI companies supported clinical-trial applications in 2024.[1]
  • 35.2% of surveyed sponsor companies and CROs had partially or fully implemented AI or machine learning for clinical-trial execution.[14]

Data Quality in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[15]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[15]
  • Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[16]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[15]
  • Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[15]

Data Governance in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[17]
  • Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[17]
  • Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[18]
  • Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[16]
  • Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[17]

KPIs in the ai pharmaceutical industry

  • 13% of surveyed life-sciences executives in 2026 reported measurable AI improvements at scale.[11]
  • 36% of surveyed pharmacovigilance organizations ranked use-case identification among their leading automation concerns.[19]
  • 71% of surveyed life-sciences executives said AI deployment had advanced at least somewhat compared with six months earlier in 2026.[11]
  • 12% of surveyed pharmacovigilance organizations allocated their IT budget to pharmacovigilance automation initiatives.[19]
  • 48% of surveyed pharmacovigilance organizations ranked regulatory concerns among their leading automation concerns.[19]
  • 35% of surveyed life-sciences executives reported significant progress in agentic AI, including enterprise-wide rollout or scaling, in 2026.[11]

06 Statistics

Strategy & Growth

Strategy & Growth emphasizes clinical speed and deal-driven buildout, with a median 6.5 years from founding to Phase 1 entry in 2026.

Growth in the ai pharmaceutical industry

  • The median employee count at clinical entry was 73 in the 2026 global analysis of AI-enabled therapeutic companies.[20]
  • The median time from company founding to Phase 1 entry was 6.5 years for clinical-stage AI-enabled therapeutic companies in 2026.[21]
  • The median operational intensity was $2.72 million per employee among AI-enabled therapeutic companies entering clinical development in 2026.[20]
  • Investor funding in AI-enabled drug discovery rose from $4.1 billion in 2023 to $8.4 billion in 2025.[3]
  • AI drug-discovery M&A activity reached 10 exits in the period analyzed by CB Insights, more than twice the sector’s historical activity.[22]
  • The median funding raised by AI-enabled therapeutic companies at clinical entry was $186.7 million in the 2026 global cohort.[20]

Differentiation in the ai pharmaceutical industry

  • AI-native biotechnology companies reached an 80% Phase I-to-Phase II clinical success rate in a 2024 analysis, versus 50% for conventional therapeutics.[23]
  • AI-native biotechnology companies reached a 40% Phase II-to-Phase III clinical success rate in a 2024 analysis, versus 24% for conventional therapeutics.[23]
  • Only approximately 15% of AI-driven drug-discovery companies had an asset in preclinical development in the cited industry analysis.[24]
  • The 2026 clinical-stage AI cohort reported a median 6.5 years from founding to Phase 1 entry, highlighting speed as a differentiating operating characteristic.[20]
  • More than 50% of AI-driven drug-discovery companies were based in the United States in the cited industry mapping.[24]

Mergers and acquisitions in the ai pharmaceutical industry

  • Takeda’s $4 billion Nimbus transaction involved acquisition of a plaque-psoriasis treatment developed by an AI-linked drug-discovery company.[22]
  • Bayer and BioNTech were singled out in the 2024 AI-readiness report for using acquisitions rather than partnerships alone in their AI strategies.[25]
  • The 2024 AI-pharma strategy report identified acquisitions as one of the three principal mechanisms used by major pharmaceutical companies to build AI capabilities.[25]
  • Takeda agreed to acquire Nimbus Therapeutics’ psoriasis treatment for $4 billion in 2023, illustrating pharma acquisition of an AI-enabled biotech asset.[22]
  • Bayer and BioNTech were identified as the only pharmaceutical companies in one 2024 report to have made acquisitions as part of their AI strategies.[25]
  • AI-focused biopharma M&A activity reached 10 total exits in the period covered by the CB Insights industry review.[22]

Strategic partnerships in the ai pharmaceutical industry

  • GSK’s 2024 data-license collaboration with Ochre Bio was valued at $37.5 million.[24]
  • AstraZeneca’s 2026 collaboration with Insitro included $40 million upfront and up to $1.46 billion in potential payments.[26]
  • Approximately 80% of AI life-sciences deals analyzed for 2014–2024 were concentrated on research and development partnerships.[13]
  • Insilico Medicine’s 2026 collaboration with Servier was valued at up to $888 million, including up to $32 million in upfront and near-term research payments.[27]
  • Pfizer’s expanded collaboration with PostEra was valued at up to $350 million in 2025.[28]

07 Statistics

People & Workforce

People & Workforce captures hiring intensity, with 1,586 open AI-related roles across 29 large pharmaceutical companies as of November 1, 2026.

Hiring in the ai pharmaceutical industry

  • GSK posted 167 open AI-related roles as of November 1, 2026, the second-highest count among the 29 companies tracked.[29]
  • Amgen posted 189 open AI-related roles as of November 1, 2026, the highest count among the 29 companies tracked.[29]
  • 1,586 open AI-related roles were listed across 29 large pharmaceutical companies as of November 1, 2026.[29]
  • The median posted U.S. pay range for 556 open AI-related pharmaceutical roles was $150,800 to $236,500 as of November 1, 2026.[29]
  • Only 17% of small biopharma companies and 46% of large biopharma companies reported being able to attract and hire skilled AI talent in 2024.[2]

Remote Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[30]
  • Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[31]
  • Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[32]
  • Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[30]

Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[33]
  • Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[32]
  • Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[34]
  • Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[35]

Upskilling in the ai pharmaceutical industry

  • 67% of biotech and biopharma organizations using AI identified internal upskilling as their top source of AI talent in 2026.[2]
  • Ethical AI skills recorded the largest increase in importance among skills required for pharmaceutical process automation in 2025.[4]
  • More than 40% of pharmaceutical organizations reported positive effects of automation on internal mobility and career progression in 2025.[4]
  • 21% of biotech and biopharma organizations using AI identified technology companies as their source of AI talent in 2026.[2]

Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)

  • Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[36]
  • Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[36]
  • At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[37]
  • Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[36]

Change Management in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 612 pharmaceutical-company respondents, clinical-trial innovations took an average of 69 months from planning to portfolio-wide implementation, excluding decentralized-trial adoption during COVID-19.[38]
  • Across pharmaceutical-company respondents, organizations spent almost 14 months planning and initiating clinical-trial innovations before later evaluation, adoption, and implementation stages in 2022.[38]
  • Among 125 pharmaceutical and biotechnology executives surveyed, 68% said their organizations were actively increasing investments in change management in 2023.[39]
  • Among pharmaceutical and biotechnology executives surveyed, 67% said their companies were using mergers and acquisitions to access talent or innovation in 2023.[39]
  • Among pharmaceutical and biotechnology executives surveyed, 26% expected to conduct a significant acquisition within the following 12 months in 2023.[39]

08 Statistics

Customer & Sales

Customer & Sales indicates faster response expectations in 2026, with 85% of US healthcare consumers saying they would switch to a competitor that responds faster.

Customer experience in the ai pharmaceutical industry

  • 30% of pharmaceutical website and social-media interactions were self-serve in 2025, according to a global study of HCP-facing digital assets.[40]
  • 7 points was the 2025 CXQ decline for pharmaceutical engagement in both general medicine and cardiology specialty comparisons.[40]
  • 63 was Novo Nordisk’s 2025 CXQ score, up two points from the previous year and placing it among the top three pharmaceutical firms.[40]
  • 22% of surveyed pharmaceutical healthcare professionals were traditionalists preferring face-to-face engagement in 2025.[40]
  • 59 was the 2025 United States pharmaceutical CXQ score, placing the country fourth after falling from third in 2024.[40]

Customer acquisition in the ai pharmaceutical industry

  • 85% of US healthcare consumers said in 2026 that they would switch to a competitor that responds faster, according to a healthcare buying-experience survey relevant to pharmaceutical customer acquisition.[41]
  • 47% of US healthcare consumers said in 2026 that brands using AI to assist them make consumers feel valued less, creating a documented acquisition risk for healthcare brands.[41]
  • 37% of US Boomers had used generative AI to research a high-stakes healthcare purchase in 2026, up from 11% in 2025.[41]
  • 44% of US healthcare consumers preferred calling when they needed help with a high-stakes healthcare purchase in 2026.[41]

09 Statistics

Marketing & Brand

Marketing & Brand reflects broad interest in AI-enabled marketing and omnichannel targeting, with 88% interested in analytics and AI to optimize healthcare-professional targeting in 2024.

Marketing in the ai pharmaceutical industry

  • 90% of pharmaceutical survey respondents were interested or very interested in integrating sales and marketing innovations for 2025.[42]
  • 93% of pharmaceutical survey respondents were interested or very interested in healthcare-professional omnichannel marketing for 2025.[42]
  • 88% of pharmaceutical survey respondents were interested or very interested in analytics and AI to optimize healthcare-professional targeting in 2024.[42]
  • 85% of pharmaceutical survey respondents were interested or very interested in generative AI for consumer marketing and patient support in 2024.[42]
  • 19% was the 2025 increase in biopharma brands classified as Proficient in Trinity’s digital-marketing competency analysis.[43]

Digital marketing in the ai pharmaceutical industry

  • 534 healthcare-professional-facing web and social-media assets were analyzed across 15 global pharmaceutical firms in eight countries in 2025.[40]
  • 112% was the 2025 increase in biopharma brands integrating Reddit into their social-media strategies, according to Trinity’s digital-marketing report.[43]
  • 2 points was the 2025 increase in pharmaceutical website and social-media CXQ scores among healthcare professionals.[40]
  • 15 leading global pharmaceutical firms were included in DT Consulting’s 2025 Global Digital Landscape Benchmark.[40]
  • 58 was the 2025 global digital-experience score for pharmaceutical websites and social media, up from 49 in the prior measurement.[40]

Branding in the ai pharmaceutical industry

  • 9 pharmaceutical brands were specifically identified in DT Consulting’s 2025 CX analysis as examples of strong or standout customer experience, including Triplixam, Trodelvy, Bimzelx, Rybelsus and Lynparza.[40]
  • 5 biopharma brands were classified as Transformational leaders in Trinity’s 2025 digital-marketing rankings: Hemlibra, Trelegy, Arexvy, Tezspire and Mavyret.[43]
  • 3 pharmaceutical firms—Novo Nordisk, Roche and Boehringer Ingelheim—led DT Consulting’s 2025 global digital-experience performance ranking.[40]

Social media in the ai pharmaceutical industry

  • 15 leading global pharmaceutical firms contributed 534 healthcare-professional-facing web and social-media assets to DT Consulting’s 2025 benchmark.[40]
  • 112% was the 2025 increase in biopharma brands integrating Reddit into their social-media strategy.[43]
  • 30% of pharmaceutical interactions on websites and social media were self-serve in 2025.[40]

Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)

  • 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[44]
  • 50% of healthcare and pharmaceutical marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, globally.[44]
  • 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[44]
  • 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[45]
  • 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[45]

10 Statistics

Operations & Execution

Operations & Execution points to measurable use cases in manufacturing and supply chain automation, with 18% implementing AI for real-time process optimization in 2025.

Process optimization in the ai pharmaceutical industry

  • 22% average time savings are reported for AI-assisted biomarker identification in biopharma R&D, based on a 2025 global executive survey.[16]
  • 18% of surveyed pharmaceutical and biotechnology organizations have implemented AI for real-time process optimization in CMC and clinical manufacturing in 2025.[16]
  • 28% average time savings are reported for AI-assisted target identification in biopharma R&D, based on a 2025 survey of 500 pharmaceutical and biotechnology executives globally.[16]
  • 10% of respondents at 20 biologics drug-substance manufacturing plants regularly use advanced analytics for improvement actions or real-time optimization, according to data collected from 2021 to 2024.[3]
  • 19% of surveyed pharmaceutical and biotechnology organizations have implemented AI-driven digital twins for process replication in CMC and clinical manufacturing in 2025.[16]

Operational efficiency in the ai pharmaceutical industry

  • 21% of pharmaceutical distributors surveyed use AI for supply-chain forecasting.[46]
  • 26% of pharmaceutical distributors surveyed use AI to optimize inventory management.[46]
  • 22% average time savings are reported for AI-assisted biomarker identification in pharmaceutical and biotechnology R&D in 2025.[16]
  • 20% average time savings are reported for AI-assisted compound screening in pharmaceutical and biotechnology R&D in 2025.[16]
  • 39% of pharmaceutical distributors surveyed use AI to improve workforce productivity in healthcare supply-chain operations.[46]

Quality management in the ai pharmaceutical industry

  • 21% of surveyed pharmaceutical and biotechnology organizations have implemented automated AI documentation analysis for critical process parameters and quality attributes in 2025.[16]
  • 48% of pharmaceutical supply-chain leaders report siloed or poor-quality data as a hurdle to scaling AI.[5]
  • 28% of surveyed pharmaceutical and biotechnology organizations have implemented AI-based visual inspection of manufacturing processes in 2025.[16]
  • 19% of surveyed pharmaceutical and biotechnology organizations have implemented AI-driven digital twins to support process consistency across manufacturing sites in 2025.[16]
  • 23% of surveyed pharmaceutical and biotechnology organizations have implemented AI-powered knowledge transfer and decision support for manufacturing in 2025.[16]

Supply chain in the ai pharmaceutical industry

  • 28% of pharmaceutical supply-chain leaders identify supply-chain network design and optimization as a top-three AI investment area.[47]
  • 70% of pharmaceutical supply-chain leaders cite internal resistance to change as a hurdle to scaling AI.[5]
  • 34% of pharmaceutical supply-chain leaders identify supply-chain visibility and traceability as a top-three AI investment area.[47]
  • 32% of pharmaceutical supply-chain leaders identify supply-chain risk management as a top-three AI investment area.[47]
  • 24% of pharmaceutical supply-chain leaders identify demand forecasting and planning as a top-three AI investment area.[47]

Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)

  • 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[48]
  • 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[7]
  • 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[19]
  • 12% of total API volume used in the United States was produced domestically in 2024, with most supply coming from India and the European Union.[49]
  • 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[7]

11 Statistics

Finance & Pricing

Finance & Pricing shows deal values anchored in collaboration milestones, with $29.7 billion total potential deal value for AI-based target and drug-discovery collaborations in 2025.

Pricing strategy in the ai pharmaceutical industry

  • $29.7 billion was the total potential deal value for AI-based target and drug-discovery collaborations in 2025.[24]
  • 27% of total deal value was represented by upfront payments in AI-based target and drug-discovery collaborations in 2025.[24]
  • $100 million in upfront and near-term payments was committed by DoveTree Medicines to XtalPi in an AI-enabled drug-discovery collaboration announced in 2025.[24]
  • $5.89 billion in potential milestones was attached to DoveTree Medicines’ 2025 AI-enabled drug-discovery collaboration with XtalPi.[24]
  • $41 million was the median upfront payment in AI-based target and drug-discovery collaborations in 2025.[24]

Cost reduction in the ai pharmaceutical industry

  • 13% of pharmaceutical distributors currently use AI for order fulfillment and compliance management, potentially reducing manual processing costs.[46]
  • 28% average time savings are reported for AI-assisted target identification in biopharma R&D in 2025, indicating a potential reduction in labor and cycle-time costs.[16]
  • 40% of pharmaceutical supply-chain leaders prioritize AI investment in inventory management and optimization, a use case directly associated with reducing excess inventory and stockout costs.[47]
  • 51% of pharmaceutical supply-chain leaders expect AI and machine-learning initiatives to return their investment within two to three years.[47]
  • 22% average time savings are reported for AI-assisted biomarker identification in biopharma R&D in 2025.[16]

Profitability in the ai pharmaceutical industry

  • $29.7 billion was the total potential value of AI-based target and drug-discovery collaborations announced in 2025.[24]
  • 53% of pipeline asset-indications had forecast peak sales potential below $250 million in Deloitte’s 2025 pharmaceutical-company analysis.[11]
  • $2.229 billion was the average cost to develop a drug from discovery to launch for the analyzed pharmaceutical companies in 2024.[11]
  • 17 of 20 analyzed pharmaceutical companies increased R&D spending year over year in Deloitte’s 2025 analysis.[11]
  • $5.89 billion in potential milestones was attached to the 2025 DoveTree Medicines–XtalPi AI drug-discovery collaboration.[24]

Financial planning in the ai pharmaceutical industry

  • 44% of life-sciences organizations dedicate more than 20% of their commercial budget to AI initiatives.[19]
  • 5% of life-sciences organizations dedicate less than 5% of their commercial budget to AI initiatives.[19]
  • 73% of life-sciences CEOs anticipated spending 10% to 20% of their budget on AI in the next 12 months.[50]
  • 20% of pharma and medtech companies spent at least $5 million on generative AI in 2024.[3]
  • 36% of surveyed life-sciences organizations operate at an advanced AI-maturity level with AI integrated across functions and governed centrally.[19]

12 Statistics

Product & Service

Product & Service focuses on deployment and outcomes, with 77.8% observed Phase 1 success probability for AI-enabled therapeutic assets in the 2026 clinical-stage analysis.

Product development in the ai pharmaceutical industry

  • 43% of surveyed biopharmaceutical organizations had implemented AI for target identification in drug discovery in 2025.[16]
  • 63% of surveyed biopharmaceutical executives expected most new molecular entities to originate from AI-driven platforms within the following decade.[16]
  • 67 AI-discovered molecules were still in clinical trials in 2023, up from 1 in 2015.[51]
  • 31% of surveyed biopharmaceutical organizations had implemented AI for biomarker identification in drug discovery in 2025.[16]
  • 25% of surveyed biopharmaceutical organizations had implemented AI for compound screening in drug discovery in 2025.[16]

Product lifecycle in the ai pharmaceutical industry

  • Five AI-enabled therapeutic assets had entered or completed Phase 3 by March 1, 2026.[20]
  • 18.9% of AI-enabled therapeutic assets had completed Phase 2 by March 1, 2026.[20]
  • 77.8% was the observed Phase 1 success probability for AI-enabled therapeutic assets in the 2026 clinical-stage analysis.[20]
  • 19.5% was the observed Phase 2 success probability for AI-enabled therapeutic assets in the 2026 clinical-stage analysis.[20]
  • 55.8% of AI-enabled therapeutic assets had completed Phase 1 by March 1, 2026.[20]

After-sales in the ai pharmaceutical industry

  • 48% of surveyed pharmacovigilance organizations identified regulatory concerns as a key concern in automation initiatives.[19]
  • 4% of pharmacovigilance organizations reported an 80% automation rate for signal and risk management in an industry survey.[52]
  • 36% of surveyed pharmacovigilance organizations identified use-case identification as a key concern in automation initiatives.[19]
  • 11% of surveyed pharmaceutical organizations partnered with vendors to identify pharmacovigilance automation use cases.[19]
  • 17% of surveyed pharmacovigilance organizations invested between $5 million and $20 million in automation.[19]

Value proposition in the ai pharmaceutical industry

  • 73% of surveyed biopharmaceutical executives agreed that generative AI could fundamentally transform regulatory workflows.[16]
  • 22% was the average time saving reported for AI-enabled biomarker identification by surveyed biopharmaceutical organizations.[16]
  • $5 billion to $7 billion was Deloitte's estimated peak five-year value opportunity for a top-10 biopharmaceutical company scaling AI.[11]
  • More than 60% of surveyed biopharmaceutical executives said generative AI could substantially improve clinical-trial efficiency and outcomes.[16]
  • 74% of surveyed biopharmaceutical executives saw significant potential for generative AI in drug discovery.[16]

13 Statistics

Sustainability & Ethics

Sustainability & Ethics emphasizes responsible AI definitions, with 81% of life-sciences leaders defining responsible AI as validated in a 2026 survey.

Ethics in the ai pharmaceutical industry

  • 81% of life-sciences leaders defined responsible AI as validated in a 2026 survey of pharmaceutical, biotech and medical-device companies.[53]
  • 75% of life-sciences leaders defined responsible AI as safe in a 2026 survey of pharmaceutical, biotech and medical-device companies.[53]
  • 79% of life-sciences leaders defined responsible AI as ethical in a 2026 survey of pharmaceutical, biotech and medical-device companies.[53]
  • 37% of surveyed health-sector organizations planned to establish a focused AI ethics committee or governance board in 2025.[54]
  • 54% of life-sciences leaders expressed concern about how AI is used in their organization in 2026.[53]

15 Statistics

Globalization & Expansion

Globalization & Expansion underscores cross-border participation and scale, with China accounting for approximately 30% of global drug development in a 2026 estimate.

Globalization in the ai pharmaceutical industry

  • China accounted for approximately 30% of global drug development and more than 1,200 novel candidates in a 2026 industry estimate.[67]
  • The global AI-enabled therapeutic cohort had a median of 73 employees when companies entered clinical development.[20]
  • The 2025 global landscape review reported that Chinese AI biotechnology companies were supplying drug candidates to multinational pharmaceutical companies, indicating cross-border commercialization.[20]
  • Investor funding in AI-enabled drug discovery reached $8.4 billion globally in 2025, up from $4.1 billion in 2023.[3]
  • Nearly 270 companies were identified globally as working in AI-driven drug discovery, with more than 50% based in the United States, according to a 2022 industry analysis.[24]

Cultural adaptation in the ai pharmaceutical industry

  • The interquartile range for time from founding to Phase 1 entry was 4.0–9.2 years among companies with available data in the 2026 global cohort.[21]
  • Approximately 80% of AI life-sciences deal activity analyzed for 2014–2024 was concentrated on research and development activities.[13]
  • The 2025 global platform review reported that AI-enabled drug discovery had expanded from U.S.- and Europe-centered activity toward stronger participation from China.[20]
  • Western Europe and Southeast Asia were identified as emerging regional hubs for AI-driven drug discovery companies in a 2022 industry analysis.[24]
  • More than 50% of AI-driven drug-discovery companies were headquartered in the United States in a 2022 global company mapping.[24]

Supplier management in the ai pharmaceutical industry

  • Discovery and target-identification agreements represented approximately 64% of publicly announced pharma AI deals analyzed for 2026.[68]
  • AstraZeneca agreed to pay Insitro $40 million upfront and up to $1.46 billion in potential development and commercial payments in a 2026 AI drug-discovery collaboration.[26]
  • GSK agreed to a $37.5 million data-license deal with Ochre Bio for human liver single-cell and perfused-organ data in 2024.[24]
  • Pfizer expanded its PostEra collaboration to a potential value of up to $350 million for AI-designed small molecules and antibody-drug conjugates in 2025.[28]
  • Target clinical-development agreements represented approximately 24% of publicly announced pharma AI deals analyzed for 2026.[68]

Stakeholder management in the ai pharmaceutical industry

  • The 2026 global cohort of AI-enabled therapeutic companies had a median of 73 employees when entering clinical development.[20]
  • Eight leading AI drug-discovery companies had 31 drugs in human clinical trials by April 2024: 17 in Phase I, five in Phase I/II and nine in Phase II/III.[69]
  • The global March 2026 analysis identified 129 AI-enabled therapeutics across 69 companies in interventional clinical trials.[20]
  • AI-native biotechnology companies had a clinical success rate of 40% from Phase II to Phase III in the 2024 analysis, compared with 24% for conventional therapeutics.[23]
  • AI-native biotechnology companies had a clinical success rate of 80% from Phase I to Phase II in the 2024 analysis, compared with 50% for conventional therapeutics.[23]

Distribution channels in the ai pharmaceutical industry

  • Clinical-development agreements accounted for approximately 24% of publicly announced pharma AI deals analyzed for 2026.[68]
  • Nine of 31 drugs from eight leading AI drug-discovery companies were in Phase II/III trials by April 2024.[69]
  • Enterprise-wide platform agreements accounted for approximately 12% of publicly announced pharma AI deals analyzed for 2026, representing the broadest distribution channel across the value chain.[68]
  • Five of 31 drugs from eight leading AI drug-discovery companies were in Phase I/II trials by April 2024.[69]
  • Discovery-focused agreements accounted for approximately 64% of publicly announced pharma AI deals analyzed for 2026.[68]

Key questions about the AI Pharmaceutical Industry

What is the 2025 market size for AI in pharmaceuticals?
BCC Research estimated the global AI-in-pharmaceuticals market at $3.8 billion in 2025.
How fast is the market expected to grow from 2025 to 2030?
BCC Research forecasts growth from $3.8 billion in 2025 to $15.2 billion by 2030, using a 31.7% CAGR.
Which companies lead the ai pharmaceutical industry?
Insilico Medicine leads Gitnux's 2026 ai pharmaceutical ranking with an Overall score of 9.3, with its Pharma.AI platform generating seven clinical-stage programs and 31 internal programs. Generate:Biomedicines is the runner-up at 9.2, driven by machine learning and experimentation designing protein medicines with programs in Phase 3.
What technology shifts are moving AI into core drug-development workflows?
The sector is scaling generative models, multimodal biological data, and automated design–make–test cycles to reduce discovery time and development costs.
How is the market structured by region?
North America accounted for 59.5% of the global AI-in-pharmaceuticals market in 2024 in BCC Research’s regional estimate.
Where does validation sit in the adoption curve?
Validation remains the main bottleneck as AI candidates move deeper into clinics.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, February 13). AI Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/ai-pharmaceutical-industry-statistics
MLA
Samuel Norberg. "AI Pharmaceutical Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ai-pharmaceutical-industry-statistics.
Chicago
Samuel Norberg. 2026. "AI Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/ai-pharmaceutical-industry-statistics.

Sources & references

93 sources cited across this report

  1. makingpharmaindustry.it
  2. benchling.com
  3. mckinsey.com
  4. apqc.org
  5. pharmamanufacturing.com
  6. ispe.org
  7. ppd.com
  8. pmlive.com
  9. test.benchling.com
  10. techresearchinfo.com
  11. deloitte.com
  12. insights.indegene.com
  13. ey.com
  14. appliedclinicaltrialsonline.com
  15. veeva.com
  16. capgemini.com
  17. pistoiaalliance.org
  18. resources.indegene.com
  19. iqvia.com
  20. sciencedirect.com
  21. ascopubs.org
  22. cbinsights.com
  23. pubmed.ncbi.nlm.nih.gov
  24. nature.com
  25. pugatch-consilium.com
  26. astrazeneca.com
  27. currentpartnering.com
  28. cen.acs.org
  29. hristosbilis.ai
  30. innovatebio.org
  31. jthelander.com
  32. naceweb.org
  33. biobuzz.io
  34. assets.kpmg.com
  35. massbio.org
  36. cultureamp.com
  37. amneal.com
  38. acrpnet.org
  39. crowe.com
  40. dt-consulting.com
  41. invoca.com
  42. digitalhealthcoalition.org
  43. trinitylifesciences.com
  44. brand-news.it
  45. sermo.com
  46. hda.org
  47. eco-cdn.iqpc.com
  48. glginsights.com
  49. richmondfed.org
  50. pharmtech.com
  51. ifpma.org
  52. globalforum.diaglobal.org
  53. prnewswire.com
  54. databricks.com
  55. bioxconomy.com
  56. statics.globant.com
  57. acrohealth.org
  58. lifesciencesny.org
  59. middlemarketcenter.org
  60. cpl.thalesgroup.com
  61. fortinet.com
  62. etla.fi
  63. openpharma.blog
  64. kiteworks.com
  65. insights.economistenterprise.com
  66. jscdm.org
  67. arxiv.org
  68. outsourcedpharma.com
  69. pmc.ncbi.nlm.nih.gov
  70. bccresearch.com
  71. fortunebusinessinsights.com
  72. thebusinessresearchcompany.com
  73. clarivanthealth.com
  74. bayer.com
  75. incytecorp.gcs-web.com
  76. orbismedicines.com
  77. fda.gov
  78. owkin.com
  79. assets.roche.com
  80. insilico.com
  81. investors.generatebiomedicines.com
  82. isomorphiclabs.com
  83. ir.schrodinger.com
  84. insitro.com
  85. ir.recursion.com
  86. iambic.ai
  87. ir.relaytx.com
  88. xaira.com
  89. koreajoongangdaily.com
  90. axios.com
  91. novonordisk.com
  92. techradar.com
  93. clinicalleader.com